Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georg Stussi

Showing results (61-70 of 81) with videos related to

Pageof 9
Sort By:
Blood Advances|August 11, 2020
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trialRudolf Benz, Kornelius Arn, Martin Andres, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 13, 2005
ABO blood group barrier in allogeneic bone marrow transplantation revisitedJörg D Seebach, Georg Stussi, Jakob R Passweg, et al.
Hematological Oncology|December 7, 2023
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021Jakob R Passweg, Helen Baldomero, Marc Ansari, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasmsAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Molecular Cancer Therapeutics|December 5, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid NeoplasmsAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Haematologica|April 29, 2022
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axisAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Swiss Medical Weekly|March 2, 2018
Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016Jakob R Passweg, Helen Baldomero, Marc Ansari, et al.
Leukemia|February 27, 2025
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agentsTom Reuvekamp, Lok Lam Ngai, Daphne den Hartog, et al.
Haematologica|November 2, 2020
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma modelsEugenio Gaudio, Chiara Tarantelli, Filippo Spriano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2017
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination TherapyChiara Tarantelli, Eugenio Gaudio, Alberto J Arribas, et al.
Pageof 9

Showing results (61-70 of 81) with videos related to

Sort By:
Pageof 9
Blood Advances|August 11, 2020
Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trialRudolf Benz, Kornelius Arn, Martin Andres, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 13, 2005
ABO blood group barrier in allogeneic bone marrow transplantation revisitedJörg D Seebach, Georg Stussi, Jakob R Passweg, et al.
Hematological Oncology|December 7, 2023
Hematopoietic cell transplantation and cellular therapies in Switzerland. Evolution over 25 years. A report from the stem cell transplantation and cellular therapies working groups of the SBST 1997-2021Jakob R Passweg, Helen Baldomero, Marc Ansari, et al.
Biorxiv : the Preprint Server for Biology|January 30, 2023
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasmsAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Molecular Cancer Therapeutics|December 5, 2023
ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid NeoplasmsAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Haematologica|April 29, 2022
Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axisAlberto J Arribas, Sara Napoli, Luciano Cascione, et al.
Swiss Medical Weekly|March 2, 2018
Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016Jakob R Passweg, Helen Baldomero, Marc Ansari, et al.
Leukemia|February 27, 2025
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agentsTom Reuvekamp, Lok Lam Ngai, Daphne den Hartog, et al.
Haematologica|November 2, 2020
Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma modelsEugenio Gaudio, Chiara Tarantelli, Filippo Spriano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2017
PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination TherapyChiara Tarantelli, Eugenio Gaudio, Alberto J Arribas, et al.
Pageof 9